In vivo models of pancreatic cancer provide invaluable tools for studying disease dynamics, immune infiltration and new therapeutic strategies. The orthotopic murine model can be performed on large cohorts of immunocompetent mice simultaneously, is relatively inexpensive and preserves the cognate tissue microenvironment. The quantification of T cell infiltration and cytotoxic activity within orthotopic tumors provides a useful indicator of an antitumoral response.
Introduction
This method details, from start-to-finish, the surgical procedure for generating orthotopic pancreatic tumors using a minimal amount of cellular material and the subsequent rapid dissociation of established tumors for comprehensive flow cytometry analysis of immune cell populations, including ex vivo analysis of T cell function.
. Once established, orthotopic tumors typically take around 1 month or more to grow (depending on the cell line used) and form large tumors that can be readily imaged by ultrasound or MRI to track progression and determine treatment efficacy 4, 5, 10 . However, once in exponential growth, the last phase of tumor growth can be rapid, so most treatment regimens are commenced relatively early (e.g., 14 days) 11, 12 . The immune system plays a critical role in tumor development, including in PDAC, which is characterized by an immunosuppressive tumor infiltrate with relative paucity of T cells and frequent presence of myeloid cells 13 . A high presence of T cells in PDAC confers a better prognosis 14, 15 . However, as single agents, immune checkpoint inhibitors that relieve T cell immunosuppression, such as anti-CTLA-4 16 and anti-PD-L1 17 , have not shown clinical benefit in PDAC patients, most likely because the overall T cell reactivity is very low. However, agents that prime T cell responses, such as anti-CD40, can overcome anti-PD-L1/CTLA-4 resistance 18, 19 and vaccination with GM-CSF-secreting allogeneic PDAC vaccine (GVAX) can increase the immunogenicity of PDAC tumors 20 , indicating that enhancing T cell responses forms important therapeutic avenue.
Critical to an antitumoral T cell response is the recognition of tumor-derived antigens via the T-cell receptor (TCR) and the subsequent production of cytotoxic cytokines and granules. While T cell antigen-recognition can be determined by TCR sequencing, this approach is costly and time consuming. However, quantification of tumor-infiltrating T cell subsets provides a good indication of an anti-tumoral response. Further examination of T cell activity ex vivo in terms of degranulation, cytokine production and other cytotoxic factors provides a deeper functional analysis. These assays can be performed on fresh tumor samples and many parameters of T cell function can be measured rapidly by flow cytometry.
CD8 + and CD4 + T cells produce cytokines such IFNγ and TNFα to potentiate an immune response 21 . IFNɣ induces MHCI upregulation on target cells, induces differentiation and recruitment of immune cells and aids cell death. IFNγ production by CD8 + T cells is well-characterized to be part of an antitumoral response and correlates with tumor regression 22, 23 . TNFα is another proinflammatory cytokine produced by both CD8 + and CD4 + T cells. It enhances TCR-dependent activation and the proliferation of T cells, aiding the anti-tumoral response. Upon TCR engagement, cytotoxic CD8 + T cells can undergo degranulation, where pre-formed secretory lysosomes containing cytotoxic molecules are released into the immunological synapse to cause target-cell degradation 21 . These molecules include Perforin, a protein that binds to the target cell membrane, forming pores that then disrupt membrane integrity and allow diffusion 21 or endocytosis 24 of other cytotoxic molecules, such as Granzyme B, directly into the cytoplasm of the target cell. Granzyme B is a protease that enacts the degradation of multiple proteins within the target cell, leading to cell death 21 .
The release of such molecules requires exocytosis of endosomes to the cell surface, where the endosomal marker CD107a (also known as LAMP-1) is transiently incorporated into the cell membrane 25 .
The measurement of cytokine secretion by T cells requires their isolation by either flow-assisted cell sorting or bead-based separation assays, which cannot be readily performed on large number of samples simultaneously. However, measurement of intracellular cytokines does not require any pre-isolation steps and can be easily be performed on multiple samples at one time, allowing a higher-throughput approach. As cytokines are rapidly secreted by T cells, the intracellular levels can be undetectable and thus the T cell requires stimulation to increase basal cytokine production. To assess antigen-driven cytokine production, the antigen recognized by the TCR must be presented to the T cell by a primed APC in vitro. In cases where the antigen specificity is not known, a broad stimulation approach is required. TCR stimulation can be mimicked using anti-CD3/28 beads that provide both TCR activation and costimulation, which induces cytokine production and proliferation. However, a more cost-effective alternative is the use of PMA and ionomycin, which together broadly activate signaling pathways that lead to the synthesis and release of intracellular cytokines. Specifically, PMA activates protein kinase C (PKC) and ionomycin raises intracellular Ca 2+ ions, leading to increased cell signaling. In order to preserve intracellular content of cytokines, this stimulation can be effectively combined with protein-transport inhibitors brefeldin A and monensin, which block proteins in the Golgi and thus prevent extracellular release. The use of PMA/ ionomycin is a well-established method for stimulating T cells and there is a strong correlation between extracellular-released and intracellular cytokines 26 . Stimulation of T cells with PMA and ionomycin also increases lysosome trafficking to cell membrane and thus CD107a becomes transiently integrated on the cell surface before being recycled into the cell. By including an anti-CD107a antibody during the stimulation, it is possible to use it as a marker of degranulation activity 25 . This method rapidly digests the tumors to provide a single-cell suspension. At this point, individual populations can be directly stained for flow cytometry or purified by downstream methods: flow-assisted cell sorting or magnetic-bead separation. Preparation of a single-cell suspension for flow cytometry analysis allows high-throughput analysis of multiple immune cell populations and their phenotypic markers, providing an accurate quantification of immune cell number and phenotype.
Finally, the digestion protocol described here prevents cell-surface markers loss and maintains immune cell viability, allowing immune cells to undergo further cell purification steps and culture as required. However, this method has not been tested for deriving epithelial cells from this digestion.
Protocol
Orthotopic pancreatic tumors were generated as previously described 10 in accordance with the U.K. Home Office Animal and Scientific
Procedures Act 1986 and the European Directive 2010/63/EU. All mice were monitored perioperatively for signs of pain or suffering, including but not limited to weight loss (> 15 % in 72 h or 20 % in any given period), piloerection, narrowing of eyes, raised gait, hunched appearance, as well of signs of wound infection including bleeding, redness and ulceration. Tumor growth was monitored by palpation, and additional clinical signs such as labored breathing, jaundice and cold extremities were also monitored in order to assess if signs of endpoint had been reached. All procedures should be carried out in sterile conditions. All reagents used prior to flow cytometry staining should be prepared in sterile conditions.
Orthotopic injection of tumor cells
1. Acclimate the mice in the animal facility for 7 days. 1. Around 2 h prior to surgery, shave the left-hand side of abdomen and back, then administer pre-operative analgesic subcutaneously under the scruff of the neck (Buprenorphine at 50-100 µg/kg). 2. Prepare surgical field, with a heat mat to lay mouse on and drapes for surrounding equipment and over mouse. Sterilize all surgical tools; prepare enough sets of tools for each mouse. 3. Place the mouse in a 5% isoflurane with O 2 chamber until unconscious. 4. Transfer the mouse, lying on its back, onto a heat mat and maintain anesthesia using a mask, usually at a lower 2-3% isoflurane. 5. Confirm deep anesthesia; as identified by loss of the pedal-withdrawal reflex when the hind paw is pinched and monitor breathing rate remains constant. 6. Cover the body in drape, with only the shaved portion exposed. Ensure the mouse is securely in the anesthesia mask. 7. Using a sterile cotton bud, add iodine solution in a circular motion over the shaved area: starting from the center and circling out to the edge. Repeat process again with fresh cotton bud and iodine.
2. Use scalpel to make a 1 cm incision directly above the pancreas/spleen location (upper-left quadrant). Sterile scissors may also be used to make the incision, if preferred. 1. Pull the skin apart using forceps. With new forceps, locate the peritoneal wall and use scissors to make another 1 cm incision through the peritoneal wall. 2. Extract the pancreas, which may come with the spleen, from the body using the second pair of forceps. 3. Gently invert the vial of tumor cells/basement membrane several times to mix. 4. Prepare the glass syringe with 5 µL containing 1,000 tumor cells in basement membrane and place on the heat mat for a few seconds to allow it to warm. NOTE: The brief warming of the syringe will allow the basement membrane to start solidifying, in order to make it easier to inject without leaking. However, this must be kept brief, if left too long the basement membrane will solidify completely and will not be injected. The use of a glass syringe allows a low volume to be precisely injected. 5. Hold the pancreas at the tail to extend it and insert the needle directly into the center of the pancreas, parallel to the pancreas itself with an effort to avoid visible blood vessels. NOTE: The center of the pancreas has a large area and it is easiest to inject. However, the head or tail of the pancreas may also be specifically injected if preferred. 6. Slowly inject 5 µL of basement membrane into the pancreas and hold the needle steady in the pancreas for at least 30 s after injection to allow the basement membrane to solidify and prevent leaking. The basement membrane should be visible as a small clear bubble will have formed; however, it may not be visible.
Preparation of single-cell suspension from digested tumor
1. Immediately after the digestion step, place the tube on ice to slow enzyme activity. 1. Add EDTA to achieve a final concentration of 20 mM and briefly vortex sample to mix. This will further slow enzyme activity. 2. Open the tube and rinse any tumor digest off the lid of the tube with fresh RPMI medium. 3. Prepare a 70 µm strainer (the µm size of the strainer can be altered as desired) on a 50 mL open tube, on ice. 4. Pre-wet the filter with medium. 5. Resuspend the digested cells and wash the sides of the tube using a 25 mL stripette, or larger. The wider opening of the stripette is important to allow the thick digest to pass easily. 6. Transfer all of the digest, using the 25 mL stripette, onto the strainer. 7. Mash the tumor on top of the filter using a 1 mL syringe plunger. Mash only directly up and down to minimize shear stress to cells. 8. Continuously wash cells through the strainer with RPMI. Make sure to wash with enough force to push cells through. 9. If there is still material to mash, but the RPMI stops flushing through, the strainer will be saturated. Therefore, transfer the sample into a new filter and continue. NOTE: Eventually only extracellular matrix components will remain in the filter, all single cells should have passed through.
2. Centrifuge the tube for 5 min at 300 x g and 4 °C. 1. Carefully resuspend the cell pellet in complete RPMI and pass directly through another filter to remove any extracellular matrix or large cell clumps that cannot be adequately resuspended. 2. At this point, if no stimulation is required, immediately stain the isolated cells for flow cytometry analysis by skipping to Step 6.1.
Alternatively, resuspend them in freezing medium (10% DMSO in FBS) and store at -80 °C followed by long-term storage in liquid nitrogen. NOTE: The freezing step can allow purification of immune cells at a later date; however, the quantification of immune cell subsets may require optimization to confirm that cell numbers and phenotype is not affected by the freeze/thaw process. The ex vivo T cell stimulation is best performed on fresh tumor samples. At this point the sample can be further purified by bead-based dead-cell removal or immune cell enrichment assays if required.
Preparing cells for ex vivo stimulation
1. Count the cells to achieve a concentration of 2 x 10 6 / 100 µL in complete medium (RPMI 10 % FBS, 1X penicillin and 1X streptomycin). 
Representative Results
After injecting 1000 TB32048 cells into the pancreas, orthotopic tumors take approximately 30 days to develop (Figure 1A,B) . Basement membrane leakage during surgery can cause large tumors to form directly on the peritoneal wall, which are prominently visible through the skin (Figure 1C) . We would remove these mice from the study. However, with good surgical skills the incidence of leakage is minimized. Orthotopic tumors harvested at endpoint can grow to a substantial size in C57BL/6 wild-type mice (Figure 1D) . Harvested orthotopic tumors require digestion in collagenase/ DNase for 20 min in order to achieve a single-cell suspension (Figure 2) . At this point, tumor-derived cells can be plated in a U-bottomed plate at 2 x 10 6 cells/well. The number of cells plated can be altered depending on the prevalence of T cells within the sample; the cell number can be lowered if T cells are at a high density. Control spleen or lymph node samples can also be plated at this point for stimulation. Each well is stimulated with PMA and ionomycin for 5 h and after 1 h incubation, brefeldin A and monensin are added in order to block extracellular release of cytokines (Figure 2) . After the incubation, samples are stained for extracellular epitopes and intracellular cytokines for analysis by flow cytometry (Figure 2) . (Figure 3A) . Immune cells are then gated on as CD45 + , and T cells further gated on as CD3 + from which CD4 + and CD8 + subsets are defined (Figure 3A) . A fluorescence minus one (FMO) is performed to determine background fluorescence for gating and a brefeldin A/monensin only control is performed to determine basal production of cytokines (Figure 3B-D) .
Samples of spleen and tumors
For IFNγ, incubation with brefeldin A/ monensin resulted in no increase in IFNγ over FMO control in both spleen and tumor samples. However, the addition of PMA and ionomycin increased the% of intracellular IFNɣ detectable in both splenic and tumor-derived CD4 + and CD8 + T cells.
Splenic CD4 + and CD8 + T cells, used as a positive control, have a relatively higher IFNγ production than tumor-infiltrating T cell subsets, with an average of 6.60 ± 1.5 % and 12.97 ± 3.4 % compared to 4.81 ± 1.0 % and 4.13 ± 1.3 %, indicating immunosuppression occurs within the tumor (Figure 3B and 4A) . Using the same strategy for TNFα, we visualized that a high percentage of splenic CD4 + T cells are positive for intracellular (Figure 3C, Figure 4B ).
Finally, CD107a is an endosomal marker that is expressed transiently on the cell surface during the exocytosis of cytotoxic granules and cytokines, as such, it is used as a surrogate marker for cytotoxicity. The benefit of staining for CD107a during the stimulation is that all transiently cell-surface expressed CD107a will be captured by the fluorescent-antibody. (Figure 3D and 4C) .
Overall these results highlight that orthotopic tumors can be generated from the injection of a very low number (1,000) of tumor cells into the pancreas. These tumors can be rapidly digested for the isolation of T cells for ex vivo stimulation. Detection of intracellular cytokines is possible and highlights the basal level of immunosuppression of infiltrating T cells, compared to T cells in secondary lymphoid organs. 
Discussion
In vivo models of pancreatic cancer provide invaluable tools to understand disease progression and assess new therapeutics targets 3 . The orthotopic model in particular is a cost-effective and reproducible model that can be applied in large cohorts of mice simultaneously 4, 27 . The orthotopic model also provides the cognate microenvironment and intact immune system for tumor growth, making it more appropriate than the subcutaneous and PDX-models. However, we have found that some elements of immune infiltration can differ between the orthotopic model and KPC mice, the gold-standard murine model 10 . One reason for this could be the accelerated tumor growth seen in the orthotopic model. Further differences in the density of immune cell subsets have been described between the orthotopic and subcutaneous models 3, 28 . Therefore, although the transgenic KPC model is more costly and variable 6 , key findings should be verified in a small cohort of KPC mice where possible.
The preparation of tumor cells for the orthotopic surgery is a critical step in the protocol. Cells should always be in the log phase of growth and mycoplasma-and infection-free. Orthotopic surgery should be postponed if there are any concerns over tumor cell growth. The use of basement membrane improves tumor incidence rate over injecting cells without it 29 and reduces cell leakage and thus peritoneal spread 27 . However, once suspended in basement membrane, tumor cells should be rapidly injected (within 2 hours) to avoid any cell loss. The number of tumor cells required to generate tumors is likely to be cell-line dependent, and a range of cell numbers should be tested (e.g., from 100 -100,000) which may also determine the time to reach endpoint. It is likely there will be a margin of error when preparing 1,000 cells per mouse for injection; therefore, if multiple days of surgery are required, treatment of groups should be spread equally across days to control for batch effects. Most surgical steps can be modified depending on preferences; however, care must be taken not to disturb the basement membrane when replacing the pancreas in the abdominal cavity or closing the peritoneal wall. Basement membrane leakage can cause tumor cell growth on the peritoneal wall, which form rapidly and can result in having to sacrifice the animal earlier.
Ideally, pancreatic tumors should be rapidly digested post-harvest and prepared for ex vivo stimulation immediately. However, this might not be possible if there is a large batch of tumors to harvest, in this case tumors should be kept on ice and digested in batches. The type, concentration and length of exposure to digestive enzymes have all been shown to affect a large number of surface molecules on immune cells 30, 31, 32 . The digestion time is also deliberately short to limit cell death 33 . Digested cells can be frozen down in freezing medium for long-term storage; however, some cell loss will occur when thawing. The digestion process can be less than optimal if the tumor pieces are not sufficiently diced before collagenase incubation and this will be evident as hard tumor pieces will remain in the filter after digestion. The collagenase concentration can be lowered if working with healthy pancreas or early-stage tumors; reports on extracting healthy pancreatic ductal cells use significantly lower concentrations 34 . A high degree of epithelial cell death is to be expected during the digestion; however, immune cells should tolerate the process well. Alternative methods exist to isolate viable epithelial cells for organoid growth 35 or to preserve tissue architecture 36 .
Modifications to the stimulation protocol can be made easily, depending on the desired read-out and immune cell analyzed (e.g., macrophages or B cells). The use of pan-stimulation reagents PMA/ionomycin does not discriminate for TCR-antigen specificity, making it useful when the antigen is not known. However, the production of IFNɣ is closely associated with TCR engagement 37 and both IFNɣ and TNFα production are critical in PDAC antitumoral responses 38 . PMA/ionomycin stimulation reflects the maximal capacity of T cells to produce cytokines, which might or might not be produced by the T cells within the tumor microenvironment. Endogenous production can be measured without the need for stimulation; however, levels may be far lower or undetectable. There are alternative methods to stimulate T cells: anti-CD3/28-coated beads, which also do not require antigen or indeed other immune cell populations. The benefit of this method is allowing quantification of cytokine production by specific T cell subsets without the need for separation methods. Other markers of cytotoxicity (granzyme B and Perforin A), activity (IL-2) or immunosuppression (IL-10) can also be added 21 . However, high-quality flow cytometry antibodies are not available to detect all cytokines and factors of interest. Therefore, if there are other applications such as ELISA required the stimulation can be performed without the inclusion of brefeldin A/monensin, allowing cytokine release into the supernatant. However, of note, this will permit total cell cytokine release and it will not be possible to determine which cell populations contributed.
IFNγ production is a dominant feature of an antitumoral T cell response, often used as a substitute for TCR-antigen recognition 37, 38 . Other in vivo methods that more accurately define antigen-specific responses utilize tumor cells expressing a known antigen, such as Ovalbumin or SV40. The universal antigen can then be used ex vivo to test T cell recognition or in combination with a TCR-restricted host mouse. Alternatively, where the antigen is unknown, quantification of T cell clonal expansion can be performed by bulk-TCR sequencing, or more recently single-cell TCR sequencing 39, 40 . To fully understand the state of the intratumoral T cell response, markers indicative of exhaustion or inhibitory receptors should also be measured including: CTLA-4, PD-1, LAG-3, TIM3, 2B4. As well as markers of effector T cells (CD44 hi , CD62 lo ) and proliferative activity,
